Nalidixic acid

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Nalidixic acid
Nalidixic acid.png
Systematic (IUPAC) name
1-Ethyl-7-methyl-4-oxo-[1,8]naphthyridine-3-carboxylic acid
Clinical data
AHFS/ Consumer Drug Information
Legal status
  • Not FDA approved
Routes of
Pharmacokinetic data
Protein binding 90%
Metabolism Partially Hepatic
Biological half-life 6-7 hours, significantly longer in renal impairment
CAS Registry Number 389-08-2 YesY
ATC code J01MB02
PubChem CID: 4421
DrugBank DB00779 YesY
ChemSpider 4268 YesY
KEGG D00183 YesY
ChEBI CHEBI:100147 YesY
Chemical data
Formula C12H12N2O3
Molecular mass 232.235 g/mol
 YesY (what is this?)  (verify)

Nalidixic acid (tradenames Nevigramon, Neggram, Wintomylon and WIN 18,320) is the first of the synthetic quinolone antibiotics.

In a technical sense, it is a naphthyridone, not a quinolone: its ring structure is a 1,8-naphthyridine nucleus that contains two nitrogen atoms, unlike quinoline, which has a single nitrogen atom.[1]

Synthetic quinolone antibiotics were discovered by George Lesher and coworkers as a byproduct of chloroquine manufacture in the 1960s.[1] Used clinically from 1967.[1]

Nalidixic acid is effective primarily against gram-negative bacteria, with minor anti-gram-positive activity. In lower concentrations, it acts in a bacteriostatic manner; that is, it inhibits growth and reproduction. In higher concentrations, it is bactericidal, meaning that it kills bacteria instead of merely inhibiting their growth.

It has historically been used for treating urinary tract infections, caused, for example, by Escherichia coli, Proteus, Shigella, Enterobacter, and Klebsiella. It is no longer clinically used for this indication in the USA as less toxic and more effective agents are available.

It is also a tool in studies as a regulation of bacterial division. It selectively and reversibly blocks DNA replication in susceptible bacteria. Nalidixic acid and related antibiotics inhibit a subunit of DNA gyrase and topoisomerase IV and induce formation of cleavage complexes.[2] It also inhibits the nicking-closing activity on the subunit of DNA gyrase that releases the positive binding stress on the supercoiled DNA.

Adverse effects[edit]

Hives, rash, intense itching, or fainting soon after a dose may be a sign of anaphylaxis. Common adverse effects include rash, itchy skin, blurred or double vision, halos around lights, changes in color vision, nausea, vomiting, and diarrhea. Nalidixic acid may also cause convulsions and hyperglycaemia,[3] photosensitivity reactions,[4] and sometimes haemolytic anaemia,[5][6] thrombocytopenia[7] or leukopenia. Particularly in infants and young children, has been reported occasionally increased intracranial pressure.[8][9][10]


In case of overdose the patient experiences headache, visual disturbances, balance disorders, mental confusion, metabolic acidosis and seizures.[11]

Spectrum of bacterial susceptibility and resistance[edit]

Aeromonas hydrophila, Clostridium and Haemophilus are generally susceptible to nalidixic acid, while other bacteria such as Bifidobacteria, Lactobacillus, Pseudomonas and Staphylococcus are resistant.[12]


EMME (Ethoxy Methylene Malonic Diethyl Ester)

Naldixic acid synthesis:[13][14]

See also[edit]


  1. ^ a b c Emmerson AM, Jones AM (May 2003). "The quinolones: decades of development and use" (pdf). The Journal of Antimicrobial Chemotherapy. 51 Suppl 1 (Suppl 1): 13–20. doi:10.1093/jac/dkg208. PMID 12702699. 
  2. ^ Pommier, Y.; Leo, E.; Zhang, H.; Marchand, C. (2010). "DNA topoisomerases and their poisoning by anticancer and antibacterial drugs". Chem. Biol 17: 421–433. doi:10.1016/j.chembiol.2010.04.012. PMID 20534341. 
  3. ^ Fraser AG, Harrower AD (Dec 1977). "Convulsions and hyperglycaemia associated with nalidixic acid". British Medical Journal 2 (6101): 1518. doi:10.1136/bmj.2.6101.1518. PMC 1632822. PMID 589309. 
  4. ^ Ramsay CA (Aug 1973). "Photosensitivity from nalidixic acid". Proceedings of the Royal Society of Medicine 66 (8): 747. PMC 1645105. PMID 4733958. 
  5. ^ Gilbertson C, Jones DR (Nov 1972). "Haemolytic anaemia with nalidixic acid". British Medical Journal 4 (5838): 493. doi:10.1136/bmj.4.5838.493-a. PMC 1786728. PMID 4653901. 
  6. ^ Tafani O, Mazzoli M, Landini G, Alterini B (Oct 1982). "Fatal acute immune haemolytic anaemia caused by nalidixic acid". British Medical Journal 285 (6346): 936–7. doi:10.1136/bmj.285.6346.936-a. PMC 1499997. PMID 6811074. 
  7. ^ Meyboom RH (Oct 1984). "Thrombocytopenia induced by nalidixic acid". British Medical Journal 289 (6450): 962. doi:10.1136/bmj.289.6450.962. PMC 1443179. PMID 6435742. 
  8. ^ Boréus LO, Sundström B (Jun 1967). "Intracranial hypertension in a child during treatment with nalidixic acid". British Medical Journal 2 (5554): 744–5. doi:10.1136/bmj.2.5554.744. PMC 1841777. PMID 6025983. 
  9. ^ Kremer L, Walton M, Wardle EN (Nov 1967). "Nalidixic acid and intracranial hypertension". British Medical Journal 4 (5577): 488. doi:10.1136/bmj.4.5577.488-a. PMC 1748506. PMID 6055749. 
  10. ^ Deonna T, Guignard JP (Sep 1974). "Acute intracranial hypertension after nalidixic acid administration". Archives of Disease in Childhood 49 (9): 743. doi:10.1136/adc.49.9.743. PMC 1649016. PMID 4419059. 
  11. ^ Eizadi-Mood N (Mar 2006). "Nalidixic acid overdose and metabolic acidosis". Cjem 8 (2): 78. PMID 17175866. 
  12. ^ "Nalidixic acid spectrum of bacterial susceptibility and Resistance" (pdf). Toku-E. 2011-09-14. Retrieved 2012-05-14. 
  13. ^ Lesher GY, Froelich EJ, Gruett MD, Bailey JH, Brundage RP (Sep 1962). "1,8-Naphthyridine derivatives. A new class of chemotherapeutic agents". Journal of Medicinal and Pharmaceutical Chemistry 91. doi:10.1021/jm01240a021. PMID 14056431. 
  14. ^ Logemann W, Almirante L, Caprio L (Mar 1954). "Studien in der heterocyclischen Reihe. I. Mitteil.: Eine neue Synthese der 2.4-Diamino-6-alkyl-5-aryl-pyrimidine ("Daraprim")". Chemische Berichte 87 (3): 435–439. doi:10.1002/cber.19540870324.  DE 1933463  GB 1338023  BE 612258 

External links[edit]